Forbes December 1, 2025
Without much fanfare and just before Thanksgiving weekend commenced, the Trump administration released the prices Medicare will pay for 15 top-selling prescription drugs. Negotiations led by the Centers for Medicare and Medicaid Services resulted in 44% lower net prices than health plans participating in Medicare’s outpatient pharmacy benefit program (Part D) were paying in 2024. Additionally, this figure is twice as large as the 22% achieved during the first round of negotiations.
The 15 selected drugs accounted for $42.5 billion in total Part D gross prescription drug spending last year. Medicare beneficiaries spent $1.7 billion out of pocket on these medications. The negotiated price reductions are projected to save beneficiaries an estimated $685 million in out-of-pocket costs.
The so-called maximum...
Today's Sponsors
Today's Sponsor